Accéder au contenu
Merck

Antituberculosis Drug Interactions with Membranes: A Biophysical Approach Applied to Bedaquiline.

Membranes (2019-11-02)
Marina Pinheiro, Heinz Amenitsch, Salette Reis
RÉSUMÉ

This work focuses on the interaction of the novel and representative antituberculosis (anti-TB) drug bedaquiline (BDQ) with different membrane models of eukaryotic and prokaryotic cells. The effect of BDQ on eukaryotic cell membrane models was assessed using liposomes, namely, multilamellar vesicles (MLVs) made of 1,2-dimyristoyl-rac-glycero-3-phosphocholine (DMPC) and also a mixture of DMPC and cholesterol (CHOL) (8:2 molar ratio). To mimic the prokaryotic cell membrane, 1,2-dimyristoyl-sn-glycero-3-phospho-rac-(1-glycerol) (DMPG) and 1,1'2,2'-tetra-oleoyl-cardiolipin (TOCL) were chosen. Powerful biophysical techniques were employed, including small-angle X-ray scattering (SAXS) and wide-angle X-ray scattering (WAXS), to understand the effect of BDQ on the nanostructure of the membrane models. The results showed that BDQ demonstrated a pronounced disordering effect in the bacterial cell membrane models, especially in the membrane model with cardiolipin (CL), while the human cell membrane model with large fractions of neutral phospholipids remained less affected. The membrane models and techniques provide detailed information about different aspects of the drug-membrane interaction, thus offering valuable information to better understand the effect of BDQ on their target membrane-associated enzyme as well as its side effects on the cardiovascular system.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Avanti
14:0 PC (DMPC), 1,2-dimyristoyl-sn-glycero-3-phosphocholine, powder
Avanti
Cholesterol (ovine), Avanti Research - A Croda Brand
Avanti
14:0 PC (DMPC), 1,2-dimyristoyl-sn-glycero-3-phosphocholine, chloroform
Avanti
14:0 PG, Avanti Research - A Croda Brand
Avanti
16:0-18:1 Cardiolipin, Avanti Research - A Croda Brand